Unknown

Dataset Information

0

Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy.


ABSTRACT: Gynecological tumors are malignancies with both high morbidity and mortality. To date, only a few chemotherapeutic agents have shown efficacy against these cancer types (only ovarian cancer responds to several agents, especially platinum-based combinations). Within this context, the discovery of immune checkpoint inhibitors has led to numerous clinical studies being carried out that have also demonstrated their activity in these cancer types. More recently, following the development of chimeric antigen receptor (CAR)-T cell therapy in hematological malignancies, this strategy was also tested in solid tumors, including gynecological cancers. In this article, we focus on the molecular basis of gynecological tumors that makes them potential candidates for immunotherapy. We also provide an overview of the main immunotherapy studies divided by tumor type and report on CAR technology and the studies currently underway in the area of gynecological malignancies.

SUBMITTER: Schepisi G 

PROVIDER: S-EPMC7922040 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy.

Schepisi Giuseppe G   Casadei Chiara C   Toma Ilaria I   Poti Giulia G   Iaia Maria Laura ML   Farolfi Alberto A   Conteduca Vincenza V   Lolli Cristian C   Ravaglia Giorgia G   Brighi Nicole N   Altavilla Amelia A   Martinelli Giovanni G   De Giorgi Ugo U  

Cancers 20210217 4


Gynecological tumors are malignancies with both high morbidity and mortality. To date, only a few chemotherapeutic agents have shown efficacy against these cancer types (only ovarian cancer responds to several agents, especially platinum-based combinations). Within this context, the discovery of immune checkpoint inhibitors has led to numerous clinical studies being carried out that have also demonstrated their activity in these cancer types. More recently, following the development of chimeric  ...[more]

Similar Datasets

| S-EPMC5809840 | biostudies-literature
| S-EPMC9968831 | biostudies-literature
| S-EPMC5800464 | biostudies-literature
| S-EPMC10093320 | biostudies-literature
| S-EPMC5982434 | biostudies-other
| S-EPMC5687736 | biostudies-literature
| S-EPMC5972325 | biostudies-literature
| S-EPMC10301827 | biostudies-literature
| S-EPMC9334018 | biostudies-literature
| S-EPMC5685771 | biostudies-literature